This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.
Age ≥ 18 years old at the time of diagnosis of MPN.
Polycythaemia vera
Essential thrombocythemia
Primary myelofibrosis, pre-fibrotic/early stage
None
Three study cohorts will be involved in the study. They are: Prospective cohort - Subjects will be enrolled in the study at their diagnosis of MPN. All data will be collected on-study prospectively. Partial prospective/retrospective cohort (partial-P/R) - Subjects will be enrolled in the study after they have been diagnosed of MPN for a period of time and still being followed up clinically (alive). Data from study enrollment forward will be collected prospectively at around 6-month intervals on-study. Data prior to study enrollment are the events of interest happened and will be collected retrospectively. Retrospective cohort - Subjects enrolled in the study after they were diagnosed of MPN and died/lost to follow. All data will be collected retrospectively.
Cohort
Other
Not listed
Time to progression to secondary myelofibrosis (for PV and ET)
Measured in months, from date of diagnosis of MPN to date of documentation of secondary myelofibrosis (event), death (event) or latest follow-up (censor). Patient without an event will be censored at date last known to be progression-free
Progression-free survival (PFS)
Measured in months, from date of diagnosis of MPN to the date of the first MDS or AML or death due to any cause. Patient without an event will be censored at date last known to be progression-free and alive.
Overall survival (OS)
Measured in months from the date of diagnosis of MDS until the date of death due to any cause. Patient who is alive will be censored at the date last known alive
Click on the lead sponsor to view all of their trials.
The University of Hong Kong
Lead sponsor
Novartis
Collaborator
